KPV

Four things to know · April 15, 2026

KPV overview

KPV · Oral

Lysine-Proline-Valine

Oral KPV delivers the peptide directly to the gastrointestinal tract, making it the preferred route for inflammatory bowel disease, IBS, and gut-specific inflammation.

6 studies cited

Noticed in days · Full benefit in weeks

Week 1

Typically reduced GI discomfort and bloating.

Week 2-3

Commonly improved bowel regularity, reduced gut inflammation.

Week 4-6

Significant improvement in IBD/IBS symptoms is commonly reported.

Week 6-8

Sustained gut health improvements are commonly reported.

Oral KPV delivers the peptide directly to the gastrointestinal tract, making it the preferred route for inflammatory bowel disease, IBS, and gut-specific inflammation. Three distinct protocols address different levels of gut inflammation severity.

DOSING

Oral protocols

ProtocolDoseFrequency
IBD/IBS support500mcg-1mg1-2x daily
Mild gut inflammation250-500mcgOnce daily
Acute flares1mg2x daily for 1-2 weeks, then reduce

Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.

What people report

Week 1

Typically reduced GI discomfort and bloating.

Week 2-3

Commonly improved bowel regularity, reduced gut inflammation.

Week 4-6

Significant improvement in IBD/IBS symptoms is commonly reported.

Week 6-8

Sustained gut health improvements are commonly reported.

What to know

  • Well tolerated orally with minimal side effects
  • Take on empty stomach for optimal absorption
  • Does not cause immunosuppression
  • Consult healthcare provider if on other IBD medications
HOW IT WORKS

How KPV works

Most anti-inflammatory compounds work on the surface of cells. KPV is small enough to pass through the membrane and reach the nucleus, where it blocks NF-κB, one of the body's main inflammation switches. That inside-out approach is why it's being studied for conditions where inflammation is deep and persistent.

BEST FOR

Key benefits

  • Reduces inflammation from inside the cell, not just the surface
  • Antimicrobial action alongside the anti-inflammatory effect
  • No skin pigmentation changes (unlike the full hormone it comes from)
  • Particularly promising for gut and skin inflammation
REGULATORY STATUS

Regulatory status

Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review KPV on July 23, 2026, for potential addition to the 503A bulks list. The uses under review: wound healing and inflammatory conditions.

KEY RESEARCH · 6 PAPERS CITED

Dalmasso G et al.

Gastroenterology

2008

Read paper →

Kannengiesser K et al.

Inflammatory Bowel Diseases

2008

Read paper →

Xiao B et al.

Molecular Therapy

2017

Read paper →

Land SC

International Journal of Physiology, Pathophysiology and Pharmacology

2012

Read paper →

Viennois E et al.

Cellular and Molecular Gastroenterology and Hepatology

2016

Read paper →

Cutuli M et al.

Journal of Leukocyte Biology

2000

Read paper →

The Pep Dispatch

Follow the evidence on KPV as it evolves.

Subscribe to find out what.

Next dispatch · May 2026 · Honest frequency: a few times a month

For the people who want to feel better — not just look up symptoms.